Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2099 - Prognostic significance of tumor-infiltrating lymphocytes (TILs) in patients with early-stage triple-negative breast cancer (TNBC) treated with curative resection alone (72P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Ji Hyun Park

Citation

Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655

Authors

J.H. Park1, H.J. Lee2, J. Ahn3, J.E. Kim3, K.H. Jung3, G. Gong2, S. Kim3

Author affiliations

  • 1 Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 3 Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
More

Resources

Abstract 2099

Background

Tumor infiltrating lymphocytes (TILs) has been highlighted as a reliable prognostic and predictive biomarker in patients with triple negative breast cancer (TNBC). However, there has been lack of data investigating its significance in curatively resected, early-stage TNBC without adjuvant chemotherapy.

Methods

We retrospectively collected patients with TNBC regardless of the stage and histologic subtype, who underwent curative resection alone without adjuvant chemotherapy between 1999 to 2012 at Asan Medical Center (Seoul, Korea). In addition, we explored the clinical impact of TILs in subset of pathologically node-negative or small primary (≤1.0cm) tumors.

Results

In a total of 78 patients, 71.8% were pathologically stage I, but nodal involvements were found in 12.8%. The reasons of no adjuvant chemotherapy were mostly patients’ refusal (73.1%) followed by physician’s discretion. All patients were available with TILs in surgical specimens with their median value of 26% (range, 1 to 90). During the median follow-up period of 74 months (range, 67 to 81), 21 patients (26.9%) experienced relapse, and 8 (10.3%) died of breast cancer progression. In relapsed patients, local relapse only was found in 14 patients (17.9%), whereas 7 (9.0%) accompanied distant metastases. Interestingly, TILs≤10% was significantly associated with distant metastasis at relapse (p = 0.050). Relapse with distant metastasis, pathological nodal positivity, and lower TILs were significantly correlated with inferior DSS (p 

Conclusions

TILs might be a potential prognostic marker for early-stage TNBC who treated with curative resection alone, particularly in node negative or small primary TNBC. In these subsets, patients with TILs ≤10% may benefit from adjuvant chemotherapy.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.